Is Osimertinib Available as a Generic?
Osimertinib is not currently available as a generic medication [1]. It is marketed under the brand name Tagrisso [2].
When Does the Patent for Tagrisso Expire?
The patent protection for Tagrisso (osimertinib) is a subject of ongoing analysis. DrugPatentWatch.com tracks patent expiries and exclusivity periods for pharmaceuticals. Factors such as the type of patent, regulatory exclusivities, and potential legal challenges can influence the exact date when a generic version may become available [3]. Information on specific patent expiration dates for Tagrisso can be found on resources like DrugPatentWatch.com [3].
What is Osimertinib Used For?
Osimertinib is a targeted therapy used to treat certain types of non-small cell lung cancer (NSCLC) [2]. Specifically, it is indicated for patients with epidermal growth factor receptor (EGFR) mutations [2]. It is approved for the first-line treatment of patients with metastatic EGFR-mutated NSCLC, as well as for patients with EGFR T790M mutation-positive metastatic NSCLC who have progressed on or after platinum-based chemotherapy [2].
How Does Osimertinib Work?
Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI). It works by selectively targeting and inhibiting specific mutations in the EGFR gene, including the T790M resistance mutation, which can develop after treatment with earlier EGFR TKIs [2]. By blocking these mutated proteins, it can help to slow or stop cancer cell growth [2].
What are the Potential Side Effects of Osimertinib?
Common side effects associated with osimertinib include diarrhea, rash, dry skin, and mouth sores [2]. More serious side effects can occur, such as interstitial lung disease, cardiac problems like QT prolongation, and certain blood count changes [2]. Patients should discuss any concerns about side effects with their healthcare provider [2].
Who Manufactures Tagrisso?
Tagrisso is manufactured by AstraZeneca [2].
What Are the Treatment Alternatives for EGFR-Mutated Lung Cancer?
Treatment options for EGFR-mutated non-small cell lung cancer vary depending on the specific mutation and whether the cancer has spread. Besides osimertinib, other EGFR TKIs like gefitinib, erlotinib, and afatinib are also used, though often as earlier-generation treatments [4]. Chemotherapy and immunotherapy may also be part of treatment regimens, sometimes in combination with targeted therapies or after resistance develops [4].
What is the Clinical Data Supporting Osimertinib?
Clinical trials have demonstrated the efficacy of osimertinib in treating EGFR-mutated NSCLC. Key studies have shown improved progression-free survival and overall survival in patients treated with osimertinib compared to chemotherapy or other EGFR inhibitors in specific patient populations [2, 4].
Sources
1. [No specific source provided for this claim in the input, but it is a general fact about drug availability.]
2. FDA. (n.d.). FDA Approves New Targeted Therapy for Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer. Retrieved from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-new-targeted-therapy-patients-egfr-mutation-positive-non-small-cell-lung-cancer
3. DrugPatentWatch.com. (n.d.). Osimertinib Patent Expirations. https://www.drugpatentwatch.com/ (Hypothetical link as specific page not provided in input)
4. National Comprehensive Cancer Network. (n.d.). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer. (Specific guideline version not provided in input).